Headquartered in Menlo Park, CA Fiscal year ends December NASDAQ: PACB pacb.com
PacBio (Pacific Biosciences of California) designs, develops and manufactures long-read DNA sequencing systems built on its HiFi sequencing technology. The systems serve research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology.
Its product lines are:
- The high-throughput Revio system and the benchtop Vega system.
- Consumables, including the SPRQ-Nx chemistry and Kinnex RNA sequencing kits.
- Service and other offerings.
The business uses an installed-base model in which instrument placements drive recurring consumables pull-through. After divesting its short-read sequencing assets, PacBio is focused on long-read innovation. It is expanding into clinical rare disease testing through partners such as GeneDx, into large-scale population genomics (Berry Genomics in China and the VA's Million Veteran Program via Sampled), and into AI-driven discovery through collaborations with Verily Health and TychoBio. Its products are provided for Research Use Only. Updated
A double beat still came with non-GAAP gross margin compressed to 36% from 42% a year ago, as the SPRQ-Nx chemistry now driving over half of Revio consumables revenue costs more to make. Full-year revenue guidance was narrowed to $155 million to $160 million, and the CFO is leaving.
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not…
Have you thought about adding penny stocks to your portfolio? You may be onto something. That is, as long as you choose the right stock picks. But there are risks to consider too.…
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
These companies all had initial public offerings in 2010 and are still public. Their performance since then has ranged from −97% to over 16,000%.
PacBio (Pacific Biosciences of California) designs, develops and manufactures long-read DNA sequencing systems built on its HiFi sequencing technology. The systems serve research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology.
The Wall Street consensus 12-month price target for PACB is $2.78.
